Elvina Almuradova, Ambassador at European School of Oncology, shared an article Komal Jhaveri and her colleagues authored on X:
“New in NEJM!!!
Imlunestrant shows promise in ER+/HER2- advanced breast cancer with ESR1 mutations – PFS 5.5 vs 3.8 months vs standard therapy. Adding Abemaciclib boosts PFS to 9.4 months.”
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Authors: Komal L. Jhaveri et al.
